D-alanine added to antipsychotics for the treatment of schizophrenia

Biological Psychiatry

Volumn 59, Issue 3, 2006, Pages 230-234

  Tsai, Guochuan E ^a   Yang, Pinchen ^b   Chang, Yue Cune ^d   Chong, Mian Yoon ^c  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^d TAMKANG UNIVERSITY   (Taiwan)

Author keywords

Glutamate; N methyl D aspartate; Schizophrenia; Treatment resistant

Indexed keywords

CHLORPROMAZINE; DEXTRO ALANINE; FLUPHENAZINE DECANOATE; HALOPERIDOL; NEUROLEPTIC AGENT; PIPOTIAZINE; PLACEBO; RISPERIDONE; SULPIRIDE; THIORIDAZINE; TRIFLUOPERAZINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; INSOMNIA; MALE; NAUSEA; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SYSTEMIC DISEASE; TREATMENT OUTCOME; URINE RETENTION;

ADULT; ALANINE; ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, GLYCINE; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 32144442536     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2005.06.032     Document Type: Article

References (47)

1. American Psychiatric Association Structured Clinical Interview for DSM-IV 1994 American Psychiatric Press Washington, DC
2. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 4th ed. 1994 American Psychiatric Press Washington, DC
3. N.C. Andreasen Scales for the Assessment of Negative symptoms (SANS) 1983 University of Iowa Iowa City, Iowa
4. T.R.E. Barnes A rating scale for drug-induced akathisia Br J Psychiatry 154 1989 672 676
5. W. Carpenter, R.W. Buchanan, D.C. Javitt, S.R. Marder, N.R. Schooler Is glutamatergic therapy efficacious in schizophrenia? Neuropsychopharmacology 29 2004 S110
6. A. Chairoungdua, Y. Kanai, H. Matsuo, J. Inatomi, D.K. Kim, H. Endou Identification and characterization of a novel member of the heterodimeric amino acid transporter family presumed to be associated with an unknown heavy chain J Biol Chem 276 2001 49390 49399
7. R.R. Conley, R.W. Buchanan Evaluation of treatment resistant schizophrenia Schizophr Bull 23 1997 663 673
8. J.T. Coyle The glutamatergic dysfunction hypothesis for schizophrenia Harvard Rev Psychiatry 3 1996 241 253
9. S.I. Deutsch, J. Mastropaolo, B.L. Schwartz, R.B. Rosse, J.M. Morihisa A "glutamatergic hypothesis" of schizophrenia Rationale for pharmacotherapy with glycine Clin Neuropharmacol 12 1989 1 13
10. T.S. Ehmann, I. Khanbhai, G.W. MacEwan, G.N. Smith, W.G. Honer, S. Flynn Neuropsychological correlates of the PANSS cognitive factor Psychopathology 37 2004 253 258
11. G.H. Fisher, A. D'Aniello, A. Vetere, L. Padula, G.P. Cusano, E.H. Man Free D-aspartate and D-alanine in normal and Alzheimer brain Brain Res Bull 26 1991 983 985
12. D.C. Goff, L. Herz, T. Posever, V. Shih, G. Tsai, D.C. Henderson A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients Psychopharmacology (Berl) 179 2004 144 150
13. D.C. Goff, G. Tsai, J. Levitt, E. Amico, D.S. Manoach, D. Schoenfeld A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia Arch Gen Psychiatry 56 1999 21 27
14. W. Guy ECDEU Assessment Manual for Psychopharmacology 1997 National Institute of Mental Health Rockville, MD
15. A.L. Halberstadt The phencyclidine-glutamate model of schizophrenia [review] Clin Neuropharmacol 18 1995 237 249
16. M. Hamilton A rating scale of depression J Neurol Neurosurg Psychiatry 23 1960 56 62
17. A. Hashimoto, T. Nishikawa, R. Konno, A. Niwa, Y. Yasumura, T. Oka Free D-serine, D-aspartate and D-alanine in central nervous system and serum in mutant mice lacking D-amino acid oxidase Neurosci Lett 152 1993 33 36
18. A. Hashimoto, T. Nishikawa, T. Oka, K. Takahashi D-alanine inhibits methamphetamine-induced hyperactivity in rats Eur J Pharmacol 202 1991 105 107
19. H.J. Herdon, F.M. Godfrey, A.M. Brown, S. Coulton, J.R. Evans, W.J. Cairns Pharmacological assessment of the role of the glycine transporter GlyT-1 in mediating high-affinity glycine uptake by rat cerebral cortex and cerebellum synaptosomes Neuropharmacology 41 2001 88 96
20. U. Heresco-Levy, M. Ermilov, P. Lichtenberg, G. Bar, D.C. Javitt High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia Biol Psychiatry 55 2004 165 171
21. U. Heresco-Levy, M. Ermilov, J. Shimoni, B. Shapira, G. Silipo, D.C. Javitt Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia Am J Psychiatry 159 2002 480 482
22. U. Heresco-Levy, D.C. Javitt, M. Ermilov, C. Mordel, A. Horowitz, D. Kelly Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia Br J Psychiatry 169 1996 610 617
23. U. Heresco-Levy, D.C. Javitt, M. Ermilov, C. Mordel, G. Silipo, M. Lichtenstein Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia Arch Gen Psychiatry 56 1999 29 36
24. D.C. Javitt, S.R. Zukin Recent advances in the phencyclidine model of schizophrenia Am J Psychiatry 148 1991 1301 1308
25. S.R. Kay, L.A. Opler, A. Fiszbein Positive and negative syndrome scale (PANSS) manual Schizophr Bull 13 1987 261 276
26. B. Kirkpatrick, R. Buchanan, P. McKenney The schedule for the deficit syndrome An instrument for research in schizophrenia Psychiatry Res 30 1989 119 123
27. J.H. Krystal, L.P. Karper, J.P. Seibyl, G.K. Freeman, R. Delaney, J.D. Bremner Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses Arch Gen Psychiatry 51 1994 199 214
28. A.C. Lahti, M.A. Weiler, B.A. Tamara Michaelidis, A. Parwani, C.A. Tamminga Effects of ketamine in normal and schizophrenic volunteers Neuropsychopharmacology 25 2001 455 467
29. Lane HY, Chang YC, Chiu CC, Tsai G (in press): Sarcosine (N-methylglycine) or D-serine treatment for acutely exacerbated schizophrenia: A double-blind, placebo-controlled study. Arch Gen Psychiatry.
30. J.P. Lindenmayer, R. Bernstein-Hyman, S. Grochowski Five factor model of schizophrenia. Initial validation J Nerv Ment Dis 182 1994 631 638
31. O. Lingjaerde, U.G. Ahlfors, P. Bech, S.J. Dencker, K. Elgen The UKU Side Effect Rating Scale A new comprehensive rating scale for psychotropic drugs and cross-sectional study of side effects in neuroleptic-treated patients Acta Psychiatr Scand Suppl 334 1987 1 100
32. A.K. Malhotra, D.A. Pinals, C.M. Adler, I. Elman, A. Clifton, D. Pickar Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics Neuropsychopharmacology 17 1997 141 150
33. C.J. Mcbain, N.W. Kleckner, S. Wyrick, R. Dingledine Structural requirements for activation of the glycine coagonist site of N-methyl-D-aspartate receptors expressed in xenopus Oocytes Mol Pharmacol 36 1989 556 565
34. Y. Nagata, R. Konno, A. Niwa Amino acid levels in D-alanine-administered mutant mice lacking D-amino acid oxidase Metabolism 9 1994 1153 1157
35. S.G. Potkin, J. Costa, S. Roy, J. Sramek, Y. Jin, B. Gulasekaram Glycine in the treatment of schizophrenia, theory and preliminary results H.Y. Meltzer Novel Antipsychotic Drug,New York 1992 Raven Press 179 188
36. W.H. Oldendorf Brain uptake of radiolabeled amino acids, amines, and hexoses after arterial injection Am J Physiol 221 1971 1629 1639
37. J.W. Olney, N.B. Farber Glutamate receptor dysfunction and schizophrenia Arch Gen Psychiatry 52 1995 998 1007
38. G.M. Simpson, J.W.S. Angus A rating scale for extrapyramidal side effects Acta Psychiatry Scand Suppl 212 1970 11 19
39. Y. Tanii, T. Nishikawa, A. Hashimoto, K. Takahashi Stereoselective antagonism by enantiomers of alanine and serine of phencyclidine-induced hyperactivity, stereotypy and ataxia J Pharmacol Exp Ther 269 1994 1040 1048
40. A.M. Thomson, V.E. Walker, D.M. Flynn Glycine enhances NMDA-receptor mediated synaptic potentials in neocortical slices Nature 338 1989 422 424
41. G. Tsai, J.T. Coyle Glutamatergic mechanisms in schizophrenia Annu Rev Pharmacol Toxicol 42 2001 165 179
42. G. Tsai, H.Y. Lane, P. Yang, M.Y. Chong, N. Lange Glycine transporter I inhibitor, N-methylglycine (sarcosine) added to antipsychotics for the treatment of schizophrenia Biol Psychiatry 55 2004 452 456
43. G. Tsai, R.J. Ralph-Williams, M. Martina, R. Bergeron, J. Berger-Sweeney, K.S. Dunham, Z. Jiang Gene knockout study of glycine transporter type 1 PNAS 101 2004 8485 8490
44. G. Tsai, D. van Kammen, S. Chen, M.E. Kelley, J.T. Coyle Glutamatergic neurotransmission involves structural and clinical deficits of schizophrenia Biol Psychiatry 44 1998 667 674
45. G. Tsai, P. Yang, L. Chung, N. Lange, J.T. Coyle D-serine added to antipsychotic for the treatment of schizophrenia Biol Psychiatry 44 1998 1081 1089
46. A. Umino, K. Takahashi, T. Nishikawa Characterization of the phencyclidine-induced increase in prefrontal cortical dopamine metabolism in the rat Br J Pharmacol 124 1998 377 385
47. B.N. Van Berckel, C.N. Evenblij, B.J. van Loon, M.F. Maas, M.A. van der Geld, H.J. Wynne D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics A double-blind, parallel, placebo-controlled study Neuropsychopharmacology 21 1999 203 210